HRQoL as Prognostic Value for Overall Survival in Patients with RCC Receiving ICIs

In the context of the Checkmate 214 trial, demonstrating health-related quality of life (HRQoL) benefits in patients with renal cell carcinoma (RCC) receiving immune checkpoint inhibitors (ICIs) in the first-line treatment, Professor David Cella is now ready to disclose the prognostic ability of these HRQoL data.